Floatz logo

Thalidomide

Beta-Thalassemia Major

National Institute of Blood and Marrow Transplant (NIBMT), PakistanSmall moleculePhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

30 Active assets in the Beta-Thalassemia Major cohort.

View all 50

Same molecule, other indications

Thalidomide is also rated in:

central nervous system neoplasmActive
BB
Indicative · Phase 2
70 / 100
View asset →
plasma cell myelomaActive
BB
Indicative · Phase 4
68 / 100
View asset →
uveal melanomaDormant
BB
Indicative · Phase 2
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →